Vaxart (STU:NB11) Cyclically Adjusted PB Ratio: (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB11 Vaxart Inc STU:NB11
50 GF Score
Price €0.60
! 3 Warning Signs
View Full Analysis

What is Vaxart Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vaxart  (STU:NB11) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vaxart Cyclically Adjusted PB Ratio Related Terms


Vaxart Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vaxart's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Cyclically Adjusted PB Ratio Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.08 0.06 0.12 0.11

Vaxart Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.11 0.22 0.26

STU:NB11 vs VTVT, SPRB, ENGN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PB Ratio falls into.


STU:NB11
50GF Score
Vaxart Inc STU:NB11
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vaxart's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vaxart's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.296/333.9520*333.9520
=0.296

Current CPI (Jun. 2026) = 333.9520.

Vaxart Quarterly Data

Book Value per Share CPI Adj_Book
201609 9.283 241.428 12.841
201612 7.556 241.432 10.452
201703 6.439 243.801 8.820
201706 4.736 244.955 6.457
201709 3.319 246.819 4.491
201712 2.597 246.524 3.518
201803 3.533 249.554 4.728
201806 2.679 251.989 3.550
201809 1.919 252.439 2.539
201812 1.383 251.233 1.838
201903 1.334 254.202 1.753
201906 0.888 256.143 1.158
201909 0.371 256.759 0.483
201912 0.242 256.974 0.314
202003 0.393 258.115 0.508
202006 0.372 257.797 0.482
202009 1.021 260.280 1.310
202012 0.920 260.474 1.180
202103 1.255 264.877 1.582
202106 1.350 271.696 1.659
202109 1.390 274.310 1.692
202112 1.321 278.802 1.582
202203 1.200 287.504 1.394
202206 1.071 296.311 1.207
202209 0.963 296.808 1.084
202212 0.778 296.797 0.875
202303 0.618 301.836 0.684
202306 0.517 305.109 0.566
202309 0.441 307.789 0.478
202312 0.345 306.746 0.376
202403 0.290 312.332 0.310
202406 0.327 314.175 0.348
202409 0.271 315.301 0.287
202412 0.247 315.605 0.261
202503 0.185 319.799 0.193
202506 0.125 322.561 0.129
202509 0.100 324.800 0.103
202512 0.312 324.054 0.322
202603 0.337 330.213 0.341
202606 0.296 333.952 0.296

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
50GF Score

Get the complete analysis for STU:NB11

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price